secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001104659-24-104920
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 5.03, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq bid price requirement
--------------------------------------------------------------------------------

- Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.
- Trading on split-adjusted basis began October 1, 2024; new CUSIP 10501E300.
- Authorized shares unchanged at 250 million; fractional shares paid in cash based on closing price.
- Reverse split also applies to warrants, options, and RSUs with proportionate adjustments.
- Split intended to increase per share bid price above $1.00 to satisfy Nasdaq continued listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/0001104659-24-104920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-104920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer